Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

By S. Shumaker, C. Legault, S. Rapp, L. Thal, R. Wallace, J. Ockene, S. Hendrix, Beverly N. Jones, A. Assaf, R. Jackson and 3 more. Journal of the American Medical Association (JAMA), 2003

2,128 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/c0d91daf0b7710f78652c7d0aeffb291cb78570a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. JoAnn E. Manson
2. F. B. Hu

Citations in the corpus

• Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. (2003, methodology): “The trial was designed to evaluate hormone therapy with respect to this reported outcome.(27,29) The analyses we report herein were conducted to provide explanatory context to the primary results of WHIMS, although the 3MSE scores were not formally planned secondary end points and the trial was not ”
• Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods (2015, background): “In general, positive (Hogervorst et al., 2000; LeBlanc et al., 2001; Rice and Morse, 2003; Weber et al., 2014) and negative (Rapp et al., 2003; Shumaker et al., 2003) effects on cognition have been reported for HRT.”
• Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. (2015, background): “Dementia Observational studies suggest a possible benefit of MHT if started in younger women closer to menopause (133), as opposed to the detrimental effects reported in clinical trials when MHT is initiated in women 65 years old (134).”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “There was also a slight increase in the risk of dementia [235] and no clinically meaningful effect on health-related quality of life such as sleep disturbance or vasomotor symptoms [236].”
• Standards of Evidence: Criteria for Efficacy, Effectiveness and Dissemination (2005, background): “A prominent recent example is the research on hormone replacement therapy for women where prior nonrandom trials suggested positive effects but a randomized trial found negative effects (Shumaker et al., 2003).”